跳至主要内容
临床试验/IRCT20190606043827N1
IRCT20190606043827N1已完成1 期

Effects of Memantine on cognitive impairment in schizophrenic patients

Kashan University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 50 years(—)
性别
All

入选标准

  • Schizophrenia according to DSM-IV criteria
  • Age 18 to 50 years
  • Receiving common drugs for schizophrenia for at least 3 months before the start of the study (Patients within 3 months of the previous 3 month antipsychotic with a constant dose of 300 to 1000 mg of chlorpromazine (except for clozapine) and a fixed dose of anticholinergic drug of 4 to 8 mg TG Phenidyl)
  • Mental Status Mini Test Score (MMSE) Between 18 and 24

排除标准

  • Dependence and drug addiction
  • History of trauma to the head
  • History of seizure
  • Severe liver and kidney function disorders
  • Severe neurological disorders
  • Receiving drugs that affect cognitive symptoms

研究者

相似试验